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Background: Species of the Scedosporium apiospermum complex (S. a complex) are emerging fungi responsible for chronic airway colonization in
cystic ﬁbrosis (CF) patients. Recent studies performed on Aspergillus fumigatus suggest that the colonization of the airways by ﬁlamentous fungi
may contribute to the progressive deterioration of lung function.
Methods:We studied S. a complex seroprevalence, as a marker of close contact between patient and the fungi, in a large monocentric cohort of CF
patients attended in a reference centre in Lyon, France.
Results: Serum samples from 373 CF patients were analysed. Antibodies against S. a complex were detected in 35 patients (9.4%). In multivariate
analysis, S. a complex seropositivity was only associated with seropositivity to A. fumigatus.
Conclusions: This study does not suggest an association between sensitization against S. a complex and poorer lung function in CF. Prospective
studies are needed to evaluate the impact of both seropositivity and S. a complex colonization on the course of CF.
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Scedosporium apiospermum is a ubiquitous filamentous fungus
initially considered the anamorph state of Pseudallescheria boydii.
However, recent taxonomic studies indicate that S. apiospermum is
a member of a species complex, called S. apiospermum complex
(S. a complex), which comprises at least five closely related but
distinct species, i.e. S. apiospermum sensu stricto (anamorph state
ofPseudallescheria apiosperma), Scedosporium boydii (anamorphby Elsevier B.V. All rights reserved.
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dehoogii and Pseudallescheria minutispora [1,2]. These fungi are
now considered as emerging opportunist pathogens due to the
recent increase in reported infections [3–5]. The spectrum of S. a
complex infections is broad, ranging from localized diseases to
multi-organ involvement and is closely related to the immunolog-
ical status of patients [6].
Along with Aspergillus fumigatus, species of the S. a complex
are currently identified as the main fungal agents responsible for
chronic airway colonization in CF patients, with a prevalence
ranging from 3.4% to 15.9% in limited monocentric studies
[7–10]. Several cases of lethal invasive S. a. complex infections
have been reported in CF patients having undergone lung
transplantation [11–14]. These patients usually developed dis-
seminated infections, affecting mostly the lungs, heart, eyes and
central nervous system in the first year post-transplantation and
died few weeks after diagnosis. Most of these patients were
colonized before transplantation which is thought to be a risk
factor of infection once the patients become immunocompro-
mised. Indeed, because mortality of Scedosporium infections is
high, S. a. complex colonization is debated as a contraindication to
transplantation by some centres. Diagnosis of Scedosporium
infections is difficult and often delayed because the clinical
symptoms are aspecific and because a positive culture of a
pulmonary specimen (i.e. sputum or bronchial aspirate) can't
allow the distinction between colonization and infection. The
diagnosis is confirmed once the fungus has been identified in
culture from a specimen obtained by a sterile procedure or when
histopathological examination reveals the presence of tissue
damages in association with hyphae. Management of S. a
complex infections is also complex due to the poor intrinsic
activity of echinocandins and triazoles against these species.
Treatmentmay thus require a combination of optimized antifungal
therapy and surgery to reduce the fungal burden. Additionally a
reduction of immunosuppression is discussed when feasible. In
contrast to the severity of Scedosporium infections in immuno-
compromised patients, colonization is mostly asymptomatic prior
to lung transplantation, although allergic bronchopulmonary
disease [8] and rare Scedosporium invasive infections have been
described in patients with diabetes mellitus [15,16].
However, the impact of long-term airway colonization by S. a
complex on respiratory function in CF patients is still unclear.
It is suggested that prolonged colonization of the airways by
A. fumigatus in CF patients may accelerate lung function
deterioration, thus increasing the risk of hospitalizations for
pulmonary exacerbations and radiological abnormalities [17–19].
Therefore one may suspect that airway colonization by species of
the S. a complex also contributes to the progressive deterioration of
lung function by enhancing the local inflammatory response [20].
A study evaluating the impact of airway colonization on CF
lung function is actually hardly achievable due to the low apparent
incidence of colonization by S. a complex among the CF
population. The rate of respiratory colonization by S. a complex
is difficult to evaluate in non-specialised centres because the
routine use of non-selective culture media for mycological
examination of sputum samples leads to a significant underesti-
mation of S. a complex detection [9,10].We decided to perform a large monocentric retrospective
study of the impact of S. a complex seroprevalence on CF
patients' outcome and to determine clinical factors associated
with seropositivity.
2. Methods
2.1. Subject population
Eligible subjects for this studywere patients diagnosedwith CF
who had at least one serum sample collected during a routine
annual visit to the pediatric or adult CF reference centre in Lyon,
France in 2008. A total of 394 patients were eligible for this study.
Patients who had undergone lung transplantation were excluded
(n = 21). Thus, 373 patients were included in this study which
was approved by the hospital Ethical Committee (2009, Hospices
Civils de Lyon).
2.2. Study design and data collection
Data were extracted from the electronic medical records of
Lyon Centre Cystic Fibrosis Database. During each visit, a sputum
is systematically collected for bacterial and fungal examination and
a serum sample is collected and stored at −20 °C in the sera bank
of our laboratory at least once a year. For each patient we selected
in the bank a serum sample collected in 2008 to assess the S. a
complex serology. Patients' clinical characteristics collected during
the same visit as the selected serum sample were extracted from the
Database. Studied parameters were age, weight, size, Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR) muta-
tions, history of previous bacterial or fungal airway colonization,
history of diabetes, ABPA (allergic bronchopulmonary aspergillo-
sis), medications, serological status towards A. fumigatus, results
from sputum fungal culture, and outcomes of pulmonary function
testing.
2.3. Serology
Serum antibodies to the S. a complex were determined in July
2009 by ELISA using a cytosolic antigenic extract obtained from
strain IHEM 15.155 (Institute of Hygiene and Epidemiology–
Mycology section; Institute of Public Health, Brussels, Belgium).
This strain originally isolated from a bronchoalveolar fluid in the
laboratory of mycology of Angers University hospital and already
used in previous studies [8,21,22] was identified by beta-tubulin
gene sequencing as P. boydii, which is the most common species
of the S. a complex in CF in France [23]. Antigenic extract was
prepared from cultures grown under stationary phase in yeast
extract–peptone–dextrose broth (containing in g per litre: yeast
extract, 10; peptone, 10 and glucose, 20). After incubation for two
weeks at 37 °C without agitation, the mycelium was harvested by
centrifugation, washed twice with sterile water, and mechanically
disrupted for 2 min with glass beads (mix of 0.25-mm and 1-mm
diameter; Braun Melsungen, Melsungen, Germany) [8]. Debris
were removed by centrifugation at 12,000 g for 30 min at 4 °C,
and the supernatant which constitutes the antigenic extract was
stored at −80 °C as aliquots until used.
Table 1
Demographic and clinical characteristics of the 373 CF patients evaluated in
2008.
Characteristics Patients
(n = 373)
Age, median (min–max), yr 15.4 (0,8;53,3) (0–53)
Sex ratio (M/F) 1.14
CFTR mutations: F508del homozygosity a 146 (39.1%)
Bronchial colonization by
S. aureus 203 (54.4%)
P. aeruginosa 156 (41.8%)
S. maltophilia 31 (8.3%)
Aspergillus fumigatus 111 (29.8%)
Scedosporium apiospermum complex 8 (2.1%)
Scedosporium prolificans 2 (0.5%)
FEV1% for patients b18 (n = 222)
b, mean (SD) 87 (20.4)
FEV1% for patients ≥18 (n = 151), mean (SD) 60 (23.6)
Prior ABPA 28 (7.5%)
Prior diabetes mellitus 35 (9.4%)
Treatment by
Azithromycin 127 (34.0%)
Systemic steroids 18 (4.8%)
Itraconazole 16 (4.3%)
Voriconazole 5 (1.3%)
Inhaled treatment 287 (76.9%)
Inhaled steroids 183 (49.0%)
Inhaled RhDNAse 175 (46.9%)
Inhaled antibiotics 157 (42.1%)
Inhaled bronchodilator 202 (54.2%)
CFTR — Cystic Fibrosis Transmembrane Conductance Regulator.
FEV1 — Forced Expiratory Volume in one second.
ABPA — Allergic bronchopulmonary aspergillosis.
a Missing data for 14 patients.
b Missing data for 41 patients since spirometric measures were not available
for patients younger than 6 years.
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coated with the antigenic extract diluted in 50 mM carbonate
buffer pH 9.6 (25 μg proteins per ml, 100 μl per well). After a
1-hour incubation at 37 °C, followed by three washes in 0.15 M
phosphate buffered saline (PBS) pH 7.2, 200 μl of a 3% bovine
serum albumin solution in PBSwas added to each well. The plates
were incubated overnight at 4 °C, washed three times in PBS, and
incubated for 1 h at 37 °C with sera from CF patients diluted
1:100 in PBS (100 μl per well). After washes in PBS containing
0.05% (vol/vol) Tween 20 (PBST), 100 μl of horseradish
peroxidase-conjugated goat anti-human immunoglobulin γ chain
antibodies (Rockland Immunochemicals Inc., Gilbertsville) or
anti-human immunoglobulin μ chain antibodies (Biosys Technol-
ogy, Paris, France) diluted 1:2000 in PBS was added to each well
for determination of IgG and IgM, respectively. The plates were
incubated for 1 h at 37 °C and finally washed three times in
PBST. OPD (o-phenylenediamine dihydrochloride) in a buffered
hydrogen peroxide solutionwas used for colour development. The
absorbance was measured spectrophotometrically at 492 nm. A
0.9 absorbance unit was chosen as positivity threshold, as a result
of prior unpublished analysis of sera from 49 non-CF healthy
patients with a median age of 17 years [15–18 years] consulting
for voluntary interruption of pregnancy or for sexually transmitted
diseases screening and from CF- or non CF-patients with proven
scedosporiosis (n = 5) or proven aspergillosis (n = 15), defined
by the isolation of the fungus by culture and the presence of
precipitin lines by counter-immunoelectrophoresis (CIE) using the
corresponding antigenic extract (from P. boydii or A. fumigatus).
All tests were performed in triplicate. Controls included the use of
uncoated wells and addition of PBS instead of CF sera in coated
wells.
2.4. Mycological examination of sputum samples
The results of mycological examination of sputum samples
were extracted from the mycology laboratory Database. Sputa
were inoculated onto Sabouraud dextrose agar containing
chloramphenicol and gentamicin. Plates were incubated at 37 °C
and examined twice weekly for 7 days. Fungi were identified on
the basis of their cultural features and microscopic morphology
according to standard descriptions [24].
2.5. Statistical analysis
The initial analysis used descriptive statistics to characterize
the study subjects. A univariate analysis was performed to
compare the clinical characteristics of S. a complex seropos-
itive and seronegative patients. Normality of all data was tested
by Shapiro–Wilk test. Comparison of means was done using
Student's t test when data were Gaussian and using Mann and
Whitney test in the case of non-Gaussian data. Categorical
variables were analysed using the Fisher's exact test or the χ2
test. Continuous data were compared using Student's t test.
p values b 0.05 were considered to be statistically significant.
A multivariable regression model was constructed using
Hosmer–Lemeshow test to evaluate the effect of S. a complex
seropositivity on covariates of interest defined by p b 0.2 inunivariate: detail what is entered in the model. A cut-off of p b 0.2
was chosen to limit confusion factors which are frequent in CF.
3. Results
3.1. Cohort characteristics
The demographic and clinical features of the 373 patients
included are summarized in Table 1. Patients' median age was
15.4 years (range, 0.8–53.3). They were 199 males and 174
females.
Bacterial airway colonization was reported for 272/373 patients
(72.9%), mostly plurimicrobial with 203 patients colonized by
Staphylococcus aureus, 156 by Pseudomonas aeruginosa and
31 by Stenotrophomonasmaltophilia. During the study period, 119/
373 patients (31.9%) had at least one sputum culture growing with
one or more Aspergillus species including 111 patients colonized
with A. fumigatus, 25 with Aspergillus flavus, 15 with Aspergillus
terreus and 10 with Aspergillus niger. Among these patients 36
were colonized with several species of Aspergillus. Eight patients
had S. a complex identified in sputum culture and 4 of them had
concomitant A. fumigatus colonization. Of note, two patients had
positive sputum samples for Scedosporium prolificans.
Patients' medical history included diabetes mellitus for 35
patients and ABPA for 28 (among these patients, 21 have had at
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in Lyon). 21 patients received antifungal therapy, 16 had
itraconazole and 5 voriconazole. Other therapeutics included
long-term azithromycin therapy for 127 patients and systemic
steroids for 18 patients. Most patients (287/373) had one or
several inhaled treatments: 202 received inhaled bronchodila-
tor, 183 inhaled steroids, 175 inhaled recombinant human
deoxyribonuclease and 157 received at least one course of
inhaled antibiotics during 2008.
3.2. Serology
Prior analysis of sera from non-CF healthy patients and from
CF- or non-CF patients with proven scedosporiosis or proven
aspergillosis permitted to define a cut-off value of 0.9. None of the
49 patients in the control group as well as patients with proven
aspergillosis were assessed positive for S. a complex serology by
both CIE which could be considered as a “gold standard”
serological test for fungi of the complex S. apiospermum and
ELISA, whereas all tested sera from patients with confirmed
scedosporiosis were found positive by CIE and ELISA with
absorbance values always exceeding the threshold of 0.9.
Using this threshold, antibodies against S. a complex were
detected in 35 patients (9.4%) including 3 out of 8 patients with
documented S. a complex airway colonization. The median age of
seropositive patients was 20.2 years [1.7–47.2 years] compared
to16.3 years [0.8–53.4] in seronegative patients. Distribution
of seroprevalence in the different age classes is shown in Fig. 1.
Seropositivity among patients increased during teenage years, then
was stable during adulthood (χ2 test for trend p nonsignificant).
The univariate analysis indicated that detection of serum
antibodies against S. a complex was associated with older age,
more frequent and prolonged hospitalizations, P. aeruginosa
and S. a complex airway colonization, positive A. fumigatus
serology, medical history of diabetes mellitus and ABPA, and
at last with decreased pulmonary functions defined by a Forced
Expiratory Volume in one second (FEV1) below 70% of the
predicted value (Table 2).
A regression model was generated to independently evaluate
the effect of S. a complex seropositivity on those parameters.Fig. 1. Seroprevalence of S. apiospermum complex by age claResults of multivariate analysis revealed that seropositivity to
S. a complex was significantly associated with seropositivity to
A. fumigatus only.
4. Conclusions
Here we demonstrate that immune response against S. a
complex is relatively frequent in a large cohort of CF patients.
Nearly 10% of the patients in our sample were found seropositive.
This result is consistent with reported prevalence rates of 14.3% to
15.9% for the airway colonization by these fungi based on sputum
cultures performed on highly selective culture media [9,10].
Currently, very few centres are using a selective culturemedium to
detect species of the S. a complex in CF patients. The
heterogeneity of the procedures used for mycological examination
of sputum samples (including the use of agar slants or agar plates,
the number and nature of the culture media, the temperature and
duration of incubation) leads to great variations in colonization
prevalence estimates between centres and more generally to
underestimating the burden of these fungi in CF patients [25].
The distribution of seroprevalence shows that the first exposure
to the fungus is more likely to occur during teenage years as
sensitization increases after the age of 10. This finding is consistent
with the mean age of first detection of S. apiospermum coloniza-
tion in CF patients, observed at 14.5 years (range, 7.8–21) by
Cimon et al. [8]. In addition, first isolation of A. fumigatus in
sputum of CF patients was also observed during teenage years,
between 12.3 and 14.1 years [8]. After the age of 10 years, the S. a
complex seroprevalence seems stable over time suggesting re-
petitive close contacts between the fungus and the patient during
adulthood or that sensitization persists following the first exposure.
Exposure to soil organisms could be the major source of
contamination of the patients since species of the S. a complex
are mainly recovered from ground (soil from the outdoor environ-
ment or from potted plants). Nevertheless, presence of potted
plants at home of our patients was not recorded in the Database,
and environmental studies were not performed. So it is not
possible at present to establish a link between the S. a complex
seropositivity and a higher exposure to these moulds. In addition, it
is likely that genetic factors also determine the establishment ofss in 373 CF patients Chi2 test for trend: p not significant.
Table 2
Univariate analysis and multivariate logistic regression analysis of factors associated with seropositivity to S. a complex.
Characteristics S. a complex seronegative
patients (n = 338)
S. a complex seropositive
patients (n = 35)
Simple logistic
regression
Multiple logistic
regression
p OR(95%CI) p OR(95%CI)
Age, median (min–max), yr 16.3 (0.8;53.4) 20.2 (1.7;47.2) 0.04 0.42
Hospital admissions in 2008, mean number (SD) 0.4 (1.0) 1.0 (1.6) 0.003 0.36
Number of hospitalisation days in 2008, mean (SD) 2.9 (10.8) 9.8 (21.8) 0.004 0.16
Bronchial colonization
S. aureus 188 (55.6%) 15 (42.9%) 0.15 0.11
P. aeruginosa 136 (40.2%) 20 (57.1%) 0.05 1.9 [1.0–4.0] 0.83
S. maltophilia 30 (8.9%) 1 (2.9%) NS
S. a complex colonization 5 (1.5%) 3 (8.6%) 0.03 6.2 [1.4–27.3]
Aspergillus fumigatus colonization 99 (29.3%) 12 (34.3%) NS
Aspergillus fumigatus positive serology 39 (11.5%) 11 (31.4%) 0.003 3.5 [1.6–7.7] 0.003 4.2 [1.6–10.8]
Medical history of ABPA 22 (6.5%) 6 (17.1%) 0.04 2.9 [1.1–7.9] 0.32
Diabetes mellitus 27 (8%) 8 (22.9%) 0.009 0.65
FEV1% predicted b 70 107 (31.6%) 20 (57.1%) 0.002 3.2 [1.5–6.9] 0.24
Treatment
Itraconazole 16 (4.7%) 0 (0%) NS
Voriconazole 5 (1.5%) 0 (0%) NS
Azithromycin 111 (33.4%) 16 (47.1%) 0.11 0.78
Systemic steroids 14 (4.2%) 4 (11.8%) 0.07 0.95
Aerosol therapy 257 (77.4%) 30 (88.2%) 0.14 0.76
FEV1 — Forced Expiratory Volume in one second.
ABPA — Allergic bronchopulmonary aspergillosis.
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some polymorphism in the IL-10 gene as suggested for the airway
colonization by A. fumigatus [26].
The association between S. a complex seropositivity and
decrease in lung function or hospital admissions found in
univariate analysis was no longer significant after adjustment for
covariates. The association appeared to be explained mainly by
age and confounders known to be related to lung function decline
in CF patients. However, the study population may be too small to
reveal correlations between S. a complex seropositivity and these
particular outcomes.
Interestingly, the analysis revealed no association between
sensitization to S. a complex and inhaled antibiotics while the
use of prophylactic inhaled antibiotics has been suggested to
predispose CF patients to A. fumigatus colonization [27,28].
Finally, the results of multivariate analysis showed that
seropositivity to S. a complex was significantly associated with
seropositivity to A. fumigatus. This could be explained by the
common occurrence of mixed colonization by S. a complex and
A. fumigatus. As A. fumigatus is commonly found in soil and in the
air, patients exposed to S. a complex probably have high risks of
having been exposed to A. fumigatus as well. In the study
conducted by Cimon et al. [8], almost all the patients colonized by
species of the S. a complex were also colonized by A. fumigatus
(10 out of 11 patients culture-positive for the S. a complex were
colonized by both fungal species). Nevertheless, immune cross-
reactions between the S. a complex and other fungi such as
A. fumigatus could also not be excluded. Although some of the
cell wall polysaccharides differ from one fungus to another
(peptidorhamnomannans in the S. a complex and galactomannans
in A. fumigatus), they certainly share common epitopes in theirmannan moieties. Moreover, some of the fungal cell wall
polysaccharides (chitin and ß-glucans) are common to almost all
fungi, and some cell wall, membrane, of intracellular proteins
needed for essential physiological processes in the fungal cell like
respiration, glucose catabolism and energy production or synthesis
of membrane ergosterol or cell wall polysaccharides, may also
exhibit common epitopes.
The role of fungal colonization on the evolution of the CF
lung function is currently debated [29]. Recently, Chotirmall
et al. [30] reported that repeated isolation of Candida
albicans from sputum samples predicts both FEV1 decline
and hospital-treated exacerbations in CF. Importantly, Candida
airway colonization may be linked to an increased risk of
P. aeruginosa ventilator-associated pneumonia in non-CF
patients who received mechanical ventilation for more than
2 days [31]. Likewise, a longitudinal study has shown that CF
patients persistently colonized by A. fumigatus had a higher rate
of hospital admissions for pulmonary exacerbations and a de-
creased FEV1% predicted than controls [17]. A relationship
between lung condition and fungal colonization was suggested
by the authors but not further evidenced. A later retrospective
cohort study evaluated the longitudinal effect of A. fumigatus
colonization on lung function of CF patients over a 5-year
period [28]. Differences in FEV1 between patients colonized by
A. fumigatus and non-colonized subjects were explained by
confounding factors known to be associated with lung disease
severity.
The present study is the first to evaluate the potential impact
of S. a complex seropositivity on the course of CF lung disease.
It made use of a large Database of children and adult patients
representative of the French CF registry [32].
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potential source of bias. Nevertheless, our data were extracted
from a pre-existing Database filled prospectively at every patient's
routine visit which ensures the quality of the data, and the number
of patients included is appropriate for precise conclusions. In
addition, the use of a non selective culture medium for
mycological culture of sputum samples may have lead to an
underestimation of the airway colonization by species of the S. a
complex in our cohort, due to their common association with the
more rapidly and more extensively growing fungus A. fumigatus.
Finally, the specificity of the serological method used in the study
should also be questioned as seropositivity to S. a complex was
significantly associated with seropositivity to A. fumigatus.
The pathogenicity of the S. a complex in CF patients remains
controversial before lung transplantation. To our knowledge, this
investigation represents the first large scale study attempting
to assess a relationship between exposure to fungi of the S. a
complex and CF lung disease. This study shows that a sensitiza-
tion against S. a complex is frequent in CF patients with rate in
agreement with the incidence of the airway colonization estimated
by culture on highly selective media, but not independently
associated with lung function deterioration or hospitalizations.
Further researches are needed to evaluate the impact of both
sensitization to these fungi and a chronic colonization of the
airways on the course of the CF disease.
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